Legal proceedings are for damages, costs, interest and any other compensation that the court is only considering as bard1. Tony Walker and Dr Irmgard Irminger-Finger have opened legal proceedings against the company in the Supreme Court of Victoria. They did so on behalf of the group of applicants to which they belong, to which the original founders and the main shareholders of BARD1AG SA belong. The company plans to file a full defense against the case in due course and has decided not to comment on the matter at this time. INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) refers to its pre-ANNOUNCEMENT at the ASX on February 24, 2021 regarding the legal proceedings before the Supreme Court of Victoria against the company of founding shareholder Tony Walker and former Managing Director and Chief Scientific Officer of BARD1, Dr. Irmgard Irminger-Finger (plaintiff and together B. the claim). The plaintiffs argue that INOVIQ breached various contractual obligations implicit in the share sales contracts under which it acquired BARD1AG SA and THE BARD1 technology as part of the conversion of the plaintiffs` performance shares (which have since been converted into a nominal number of ordinary shares following a shareholder resolution taken at the company`s general meeting in 2021). The company continues to challenge the basis of the claim and recently filed an amended defense in response to the changes to the plaintiffs` statement. The procedure was registered for trial in February 2023. As noted in previous announcements, INOVIQ is continuing its review of the BARD1 autoantibody program and, while this review is being conducted, no further investment in the technology is planned. A decision on further investments will be made after the completion of this review process and taking into account all relevant issues raised during the legal proceedings.
For more information, download the attached PDF file. Download this document The lawsuit concerns the performance shares issued to the plaintiffs upon the acquisition of BARD1ag for the first time. Dr. Irminger-Finger currently holds a total of 3,608,414 performance shares, while Tony Walker holds 2,950,055. If you wish to reuse some or all of the item, please use the link below that will take you to the Copyright Clearance Center`s RightsLink service. You`ll be able to get a quick price and instant permission to reuse content in different ways. Based on the published data, the role of BARD1 in breast cancer susceptibility remains ambiguous and undoubtedly warrants further studies. According to the results of the present study, people heterozygous for the Cys557Ser allele appear to have an increased risk of breast cancer. The observed incidence of 7.4% in the breast cancer families studied compared to 1.4% in healthy controls suggests that it may be a relatively common susceptibility allele associated with incomplete disease penetration. However, in the absence of direct functional tests, the importance of Cys557Ser for the development of breast cancer cannot be properly assessed.
Therefore, despite interesting results, even more in-depth studies will be needed to investigate the role of BARD1 in breast cancer predisposition. It is not known whether men with a BARD1 change have an increased risk of cancer, and it is possible that this mutation increases the risk of other cancers in both men and women. See identical proteins and their annotated sites for NP_000456.2 Cys557Ser was the only possible disease-related change in BARD1 observed in the present study. Of the index cases of the breast and/or ovarian cancer families studied, 5.6% (7/126) were found to be heterozygous for the Cys557Ser allele. The same change was also observed in 1.4% of controls without cancer (n = 1018), but with a significantly lower incidence (p = 0.005; OR 4.2; 95% CI 1.7 to 10.7). Interestingly, in the genetic material, the seven index cases with Cys557Ser belong to a subgroup of 94 families that have breast cancer but not ovarian cancer, resulting in a prevalence of 7.4% (p=0.001; OR 5.8; 95% CI 2.3 to 14.7).